ME02100B - Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora - Google Patents

Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora

Info

Publication number
ME02100B
ME02100B MEP-2015-55A MEP5515A ME02100B ME 02100 B ME02100 B ME 02100B ME P5515 A MEP5515 A ME P5515A ME 02100 B ME02100 B ME 02100B
Authority
ME
Montenegro
Prior art keywords
pyrazol
pyrimidin
bromo
amine
disease
Prior art date
Application number
MEP-2015-55A
Other languages
English (en)
Inventor
Gómez Juan Alberto Camacho
Laria Julio Cesar Castro-Palomino
Original Assignee
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma Sl filed Critical Palobiofarma Sl
Publication of ME02100B publication Critical patent/ME02100B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)

Claims (18)

1. Jedinjenje formule (I):gde- R1 predstavlja petočlani heteroaril prsten izabran od pirazol, tiazol, ili triazol prstenova po izboru supstituisanih sa jednim ili dva halogena atoma ili jednom ili dve metil ili trifluorometil grupe- R2 predstavlja vodonikov atom- R3 predstavlja atom broma, atom hlora ili cijano grupu- R4 predstavlja nezavisno:a) petočlanu heteroaril grupu po izboru supstituisanu jednim ili više halogenih atoma ili jednom ili više C1-C8 alkil, cikloalkil, C1-C8 alkoksi, C1-C8 alkiltio, amino, mono- ili di-C1-C8 alkilamino grupab) grupu -N(R5)(R6) u kojoj R5 i R6 predstavljaju nezavisno:- vodonikov atom- alkil ili cikloalkil grupu od 3 do 6 ugljenikovih atoma, linearnu ili razgranatu, po izboru supstituisanu sa jednim ili više halogenih atoma ili jednom ili više cikloalkil, hidroksi, C1-C8 alkoksi, amino, mono- ili di- C1-C8 alkilamino grupa- ili R5 i R6 formiraju zajedno sa azotovim atomom za koji su vezani zasićenu heterocikličnu grupu sa od 4 do 6 članova u koju dalje može biti uveden heteroatom, koji je po izboru supstituisan sa jednim ili više halogenih atoma ili jednom ili više C1-C8 alkil, hidroksi, C1-C8 alkoksi, amino, mono- ili di- C1-C8 alkilamino grupa,ilic) grupu -OR7 ili -SR7, gde R7 predstavlja nezavisno:- C1-C8 alkil ili cikloalkil grupu, linearnu ili razgranatu, po izboru supstituisanu sa jednim ili više halogenih atoma ili sa jednom ili više C1-C8 alkil, C1-C8 alkoksi, amino, mono- ili di- C1-C8 alkilamino grupa- Fenil prsten po izboru supstituisan sa jednim ili više halogenih atoma ili njihovom farmaceutski prihvatljivom soli
2. Jedinjenje prema patentnom zahtevu 1 u kome R4 predstavlja pirazolski prsten vezan na položaju 2 pirimidinskog prstena preko azotovog atoma pirazolskog prstena, gde je ovaj pirazolski prsten po izboru supstituisan sa jednim ili dva halogena atoma ili sa jednom ili dve metil grupe.
3. Jedinjenje prema patentnom zahtevu 1 u kome R4 predstavlja 2-tiazolil prsten, gde je ovaj tiazolski prsten po izboru supstituisan sa jednim ili dva halogena atoma ili sa jednom ili dve metil grupe.
4. Jedinjenje prema patentnom zahtevu 1 u kome R4 predstavlja grupu -N(R5)(R6) kao što je definisano u patentnom zahtevu 1.
5. Jedinjenje prema patentnom zahtevu 4 u kome R5 predstavlja vodonikov atom i R6 predstavlja alkil ili cikloalkil grupu sa 3 do 6 ugljenikovih atoma, linearnu ili razgranatu, po izboru supstituisanu sa halogenim atomima, amino, C1-C8 alkilamino.
6. Jedinjenje prema patentnom zahtevu 1 u kome R3 predstavlja atom broma ili hlora.
7. Jedinjenje prema patentnom zahtevu 6 u kome R1 predstavlja pirazolski ili tiazolski prsten od kojih su oba po izboru supstituisana sa jednim ili dva halogena atoma ili sa jednom ili dve metil ili trifluorometil grupe, i R4 predstavlja pirazolski ili tiazolski prsten od kojih su oba po izboru supstituisana sa jednim ili dva halogena atoma ili sa jednom ili dve metil grupe.
8. Jedinjenje prema patentnom zahtevu 6 u kome R1 predstavlja pirazolski prsten po izboru supstituisan sa jednim ili dva halogena atoma ili sa metil ili trifluorometil grupama, i R4 predstavlja pirazolski prsten po izboru supstituisan sa jednim ili dva halogena atoma ili sa metil grupama.
9. Jedinjenje prema patentnom zahtevu 6 u kome R1 predstavlja pirazol ili tiazol prstenove po izboru supstituisane sa jednim ili dva halogena atoma, metil ili trifluorometil grupama, i R4 predstavlja grupu -N(R5)(R6).
10. Jedinjenje prema patentnom zahtevu 6 u kome R1 predstavlja pirazol ili tiazol prstenove po izboru supstituisane sa jednim ili dva halogena atoma, metil ili trifluorometil grupama, i R4 predstavlja grupu SR7 ili OR7, gde R7 predstavlja linearnu ili razgranatu C1-C8 alkil grupu po izboru supstituisanu sa atomima fluora.
11. Jedinjenje prema patentnom zahtevu 1 koje je jedno od: 5-brom-2,6-di-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(4-metil-1H-pirazol-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-2-(1H-pirazol-1-il)-6-(pirolidin-1-il)pirimidin-4-amina 5-brom-N4-ciklopentil-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-6-(piperidin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-morfolino-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(4-metilpiperazin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-N4-ciklopropil-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 6-(azetidin-1-il)-5-brom-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-N4-ciklobutil-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-6-(2-metilpirolidin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-((R)-2-metilpirolidin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 1-[6-amino-5-brom-2-(1H-pirazol-1-il)pirimidin-4-il]azetidin-3-ola 1-[6-amino-5-brom-2-(1H-pirazol-1-il)pirimidin-4-il]pirolidin-3-ola 5-brom-6-((S)-3-fluoropirolidin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-[(S)-3-(dimetilamino)pirolidin-1-il]-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(2,5-dimetilpirolidin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(3,3-difluoroazetidin-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-N4-izopropil-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-N4-propil-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-hlor-2,6-di-(1H-pirazol-1-il)pirimidin-4-amina 4-amino-2,6-di-(1H-pirazol-1-il)pirimidin-5-karbonitrila 4-amino-6-N-ciklopentilamino-2-(1H-pirazol-1-il)pirimidin-5-karbonitrita N4-terc-butil-5-brom-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-2-(4-metil-1H-pirazol-1-il)-6-(1H-pirazol-1-il)pirimidin-4-amina 6-(azetidin-1-il)-5-brom-2-(4-metil-1H-pirazol-1-il)pirimidin-4-amina 5-brom-N4-ciklopentil-2-(4-metil-1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-N4-ciklopropil-2-(4-metil-1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-N4-ciklobutil-2-(4-metil-1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-2-(4-metil-1H-pirazol-1-il)-6-(2-metilpirolidin-1-il)pirimidin-4-amina 5-brom-2-(4-metil-1H-pirazol-1-il)-6-((R)-2-metilpirolidin-1-il)pirimidin-4-amina 5-brom-N-ciklopropil-2-(4-hlor-1H-pirazol-1-il)pirimidin-4,6-diamina 6-(azetidin-1-il)-5-brom-2-(4-hlor-1H-pirazol-1-il)pirimidin-4-amina 5-brom-2,6-di-(4-metil-1H-pirazol-1-il)pirimidin-4-amina 5-brom-2,6-di-(4-hlor-1H-pirazol-1-il)pirimidin-4-amina 5-brom-2,6-di-(3-metil-1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(3,5-dimetil-1H-pirazol-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(1H-imidazol-1-il)-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-6-(4-hlor-1H-pirazol-1-il)-2(1H-pirazol-1-il)pirimidin-4-amina 5-brom-2-(1H-pirazol-1-il)-6-(2H-1,2,3-triazol-2-il)pirimidin-4-amina 5-brom-2-(1H-pirazol-1-il)-6-(1H-1,2,4-triazol-1-il)pirimidin-4-amina 5-brom-6-izopropoksi-2-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-2-(4-hlor-1H-pirazol-1-il)-6-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-2-(4-hlor-1H-pirazol-1-il)-6-(4-metil-1H-pirazol-1-il)pirimidin-4-amina 5-brom-2-(3,5-dimetil-1H-pirazol-1-il)-6-(1H-pirazol-1-il)pirimidin-4-amina 5-brom-N4-ciklopentil-2-(3,5-dimetil-1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-2-(3,5-dimetil-1H-pirazol-1-il)-6-(pirolidin-1-il)pirimidin-4-amina 5-brom-N4-izopropil-2-(3,5-dimetil-1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-2,6-bis(3,5-dimetil-1H-pirazol-1-il)pirimidin-4-amina 5-Brom-2,6-di(tiazol-2-il)pirimidin-4-amina 5-Brom-2-(1H-pirazol-1-il)-6-(tiazol-2-il)pirimidin-4-amina 5-Brom-6-(1H-pirazol-1-il)-2-(tiazol-2-il)pirimidin-4-amina 5-brom-N4-[1-(dimetilamino)propan-2-il]-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-N4-(1-metoksipropan-2-il)-2-(1H-pirazol-1-il)pirimidin-4,6-diamina 5-brom-6-(1H-pirazol-1-il)-2-(2H-1,2,3-triazol-2-il)pirimidin-4-amina 5-brom-6-etoksi-2-(1H-pirazol-1-il)pirimidin-4-amina.
12. Jedinjenje prema bilo kojem od patentnih zahteva od 1 do 11 za primenu u lečenju patološkog stanja ili oboljenja koje je podložno ublaženju antagonizmom adenozinskog A2a receptora.
13. Jedinjenje prema patentnom zahtevu od 1 do 11 za primenu u lečenju patološkog stanja ili oboljenja gde je patološko stanje ili oboljenje ishemija, supraventrikularna aritmija, atrijalna fibrilacija, akutna bubrežna insuficijencija, miokardijalna reperfuziona povreda, oboljenja usled zadržavanja tečnosti, alergijske reakcije uključujući ali ne limitirajući se na rinitis, urtikariju, sklerodermu, artritis, druga autoimuna oboljenja, inflamatornu bolest creva, diabetes mellitus, gojaznost, Parkinsonovu bolest, Hantingtonovu bolest, distonije kao što su sindrom nemirnih nogu, diskinezije kao što su one izazvane produženom primenom dopamina ili neuroleptičkih lekova ili poremećajima spavanja, kongestivnom srčanom insuficijencijom, hipertenzijom, intradilatacijskom hipotenzijom, demencijom, anksioznim poremećajima i glaukomom.
14. Jedinjenje prema patentnom zahtevu 13 za primenu u lečenju patološkog stanja ili oboljenja gde su patološka stanja ili oboljenja aritmije, atrijalna fibrilacija, Parkinsonova bolest, Hantingtonova bolest, Alchajmerova bolest, distonije kao što su sindrom nemirnih nogu, diskinezije kao što su one izazvane produženom primenom dopamina ili neuroleptičkih lekova ili poremećajima spavanja, demencijom, anksioznim poremećajima i diabetes mellitus-om.
15. Farmaceutska kompozicija koja sadrži jedinjenje koje je definisano u bilo kom od patentnih zahteva od 1 do 11 pomešana sa farmaceutski prihvatljivim rastvaračem ili nosačem.
16. Kombinovani proizvod koji sadrži jedinjenje prema bilo kom od patentnih zahteva od 1 do 11 i još jedno jedinjenje za lečenje oboljenja kao što su ishemija, supraventrikularna aritmija, atrijalna fibrilacija, akutna bubrežna insuficijencija, miokardijalna reperfuziona povreda, oboljenja usled zadržavanja tečnosti, alergijske reakcije uključujući ali ne limitirajući se na rinitis, urtikariju, sklerodermu, artritis, druga autoimuna oboljenja, inflamatornu bolest creva, diabetes mellitus, gojaznost, Parkinsonovu bolest, Hantingtonovu bolest, Alchajmerovu bolest, distonije kao što su sindrom nemirnih nogu, diskinezije kao što su one izazvane produženom primenom dopamina ili neuroleptičkih lekova ili poremećajima spavanja, kongestivnom srčanom insuficijencijom, hipertenzijom, intradilatacijskom hipotenzijom, demencijom, anksioznim poremećajima i diabetes mellitus-om, za istovremenu, odvojenu ili sekvencijalnu primenu.
17. Kombinovani proizvod koji sadrži jedinjenje prema bilo kom od patentnih zahteva od 1 do 11 sa levodopom, agonistima dopamina, MAO-B inhibitorima, inhibitorima acetilholin esteraze ili bilo kojim lekom koji se koristi za lečenje Parkinsonove bolesti, Hantingtonove bolesti i Alchajmerove bolesti.
18. Kombinovani proizvod koji sadrži jedinjenje prema bilo kom od patentnih zahteva od 1 do 11 sa insulinom, metforminom, GLP-agonistima, sulfonilureama, DPP-IV inhibitorima ili bilo kojim lekom koji se koristi za lečenje dijabetesa.
MEP-2015-55A 2010-03-31 2011-03-29 Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora ME02100B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201030489A ES2365960B1 (es) 2010-03-31 2010-03-31 Nuevos antagonistas de los receptores de adenosina.
EP11719879.6A EP2552909B1 (en) 2010-03-31 2011-03-29 4-aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
PCT/IB2011/000664 WO2011121418A1 (en) 2010-03-31 2011-03-29 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
ME02100B true ME02100B (me) 2015-10-20

Family

ID=44120157

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-55A ME02100B (me) 2010-03-31 2011-03-29 Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora

Country Status (22)

Country Link
US (1) US8796284B2 (me)
EP (1) EP2552909B1 (me)
JP (1) JP5725383B2 (me)
KR (1) KR101441781B1 (me)
CN (1) CN102892761B (me)
AU (1) AU2011234144B2 (me)
BR (1) BR112012024870B1 (me)
CA (1) CA2795009C (me)
CY (1) CY1116328T1 (me)
DK (1) DK2552909T3 (me)
EA (1) EA021565B1 (me)
ES (2) ES2365960B1 (me)
HR (1) HRP20150366T1 (me)
ME (1) ME02100B (me)
MX (1) MX2012011240A (me)
PL (1) PL2552909T3 (me)
PT (1) PT2552909E (me)
RS (1) RS53939B1 (me)
SI (1) SI2552909T1 (me)
SM (1) SMT201500097B (me)
WO (1) WO2011121418A1 (me)
ZA (1) ZA201207259B (me)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
NZ746607A (en) * 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
ES2480341B1 (es) * 2013-01-24 2015-01-22 Palobiofarma S.L Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN103626741A (zh) * 2013-11-26 2014-03-12 苏州大学 具有腺苷受体拮抗剂活性的杂环氨基嘧啶化合物
CN103664908A (zh) * 2013-12-10 2014-03-26 苏州大学 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物
EP3324974B1 (en) * 2015-07-24 2022-06-08 University Of Louisville Research Foundation, Inc. Compounds, compositions, methods for treating diseases, and methods for preparing compounds
HUE046646T2 (hu) * 2015-08-11 2020-03-30 Novartis Ag 5-bróm-2,6-di-(1H-pirazol-1-il)pirimidin-4-amin rák kezelésénél történõ alkalmazásra
MX373318B (es) * 2015-08-11 2020-05-21 Novartis Ag 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
CA3058492A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
CA3058503A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
CN106543416A (zh) * 2016-10-21 2017-03-29 新疆大学 含嘧啶的聚合物在dmf溶液中检测硫酸浓度方面的应用
HUE057337T2 (hu) * 2017-02-10 2022-05-28 Novartis Ag 1-(4-amino-5-bróm-6-(1H-pirazol-1-il)pirimidin-2-il)-1H-pirazol-4-ol és alkalmazása rák kezelésében
JP7273732B2 (ja) * 2017-05-31 2023-05-15 ノバルティス アーゲー ５－ブロモ－２，６－ジ（１ｈ－ピラゾール－１－イル）ピリミジン－４－アミン及び新たな塩の結晶形
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
CN107286146B (zh) * 2017-07-05 2020-07-31 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
CA3090922A1 (en) * 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
KR20230020023A (ko) 2018-03-14 2023-02-09 서피스 온콜로지, 인크. Cd39에 결합하는 항체 및 이의 용도
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
KR102870868B1 (ko) 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
CA3100923A1 (en) 2018-06-04 2019-12-12 Exscientia Ltd Pyrazolopyrimidine compounds as adenosine receptor antagonists
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN112154144B (zh) * 2018-07-13 2022-05-27 江苏恒瑞医药股份有限公司 一种1,2,4-三嗪-3-胺类衍生物的晶型及制备方法
EP3836932A2 (en) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
BE1026612B1 (fr) 2018-09-27 2020-07-02 Iteos Therapeutics S A Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine
IL281802B2 (en) * 2018-09-27 2025-10-01 iTeos Belgium SA Use of an ENT family transporter inhibitor in cancer treatment and its combination with an adenosine receptor antagonist
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
JP2022514087A (ja) 2018-12-21 2022-02-09 ノバルティス アーゲー ＩＬ－１β結合抗体の使用
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
MX2022003719A (es) 2019-09-25 2022-04-26 Surface Oncology Inc Anticuerpos anti-il-27 y sus usos.
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
EP4110784A1 (en) 2020-02-26 2023-01-04 iTeos Belgium SA Pyrimido[5,4-d]pyrimidine derivatives as ent inhibitors for the treatment of cancers, and combination thereof with adenosine receptor antagonists
JP7654008B2 (ja) * 2020-03-16 2025-03-31 上海海雁医薬科技有限公司 置換ピリミジンまたはピリジルアミン誘導体、その組成物及び医薬的使用
CN113429410B (zh) * 2020-03-23 2022-10-04 上海海雁医药科技有限公司 多杂环取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途
CN115397818A (zh) * 2020-03-27 2022-11-25 东亚St株式会社 氨基嘧啶衍生物及其作为芳烃受体调节剂的应用
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection
KR20230007369A (ko) 2020-04-07 2023-01-12 아이테오스 벨지움 에스에이 암의 치료를 위한 ent 저해제로서의 거대환식 다이아민 유도체 및 이와 아데노신 수용체 길항제와의 조합물
CN111362939B (zh) * 2020-04-26 2021-08-03 山东梅奥华卫科技有限公司 一种帕布昔利布母核结构化合物的制备方法
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
CA3199095A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
US20240141060A1 (en) 2021-01-29 2024-05-02 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
EP4294948A1 (en) 2021-02-17 2023-12-27 iTeos Belgium SA Compounds, compositions and methods of treatment thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
AU2022347682B2 (en) * 2021-09-15 2025-08-28 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Polymorph and application of pyrimidine derivative and pharmaceutically acceptable salt thereof
KR102938640B1 (ko) 2022-07-22 2026-03-16 퓨쳐메디신 주식회사 아데노신 수용체에 작용하는 리간드 내지 이를 포함하는 비만 예방, 개선 또는 치료용 조성물
WO2024134541A1 (en) 2022-12-20 2024-06-27 iTeos Belgium SA Heterocyclic compounds as ent inhibitors and compounds for use in the treatment of cancers
TW202523332A (zh) 2023-11-14 2025-06-16 比利時商艾托斯比利時公司 Ｅｎｔ１抑制劑與檢查點抑制劑組合

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
WO2001062233A2 (en) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
ATE407678T1 (de) * 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI330183B (me) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
CA2551944A1 (en) * 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
EP1894930A4 (en) * 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
JP2010511727A (ja) * 2006-12-04 2010-04-15 ニューロクライン バイオサイエンシーズ，インコーポレイテッド アデノシン受容体アンタゴニストとしての置換ピリミジン
WO2008110891A2 (en) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
WO2008116185A2 (en) 2007-03-21 2008-09-25 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
AU2008296479A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis

Also Published As

Publication number Publication date
KR101441781B1 (ko) 2014-09-17
AU2011234144B2 (en) 2014-04-24
SI2552909T1 (sl) 2015-06-30
EP2552909B1 (en) 2015-03-11
ES2365960A1 (es) 2011-10-14
WO2011121418A1 (en) 2011-10-06
CN102892761A (zh) 2013-01-23
JP5725383B2 (ja) 2015-05-27
US20130053308A1 (en) 2013-02-28
DK2552909T3 (en) 2015-04-13
PL2552909T3 (pl) 2015-08-31
SMT201500097B (it) 2015-07-09
PT2552909E (pt) 2015-04-23
WO2011121418A9 (en) 2012-04-05
RS53939B1 (sr) 2015-08-31
CA2795009A1 (en) 2011-10-06
CY1116328T1 (el) 2017-02-08
ZA201207259B (en) 2013-09-25
AU2011234144A1 (en) 2012-10-25
ES2534227T3 (es) 2015-04-20
HRP20150366T1 (hr) 2015-05-22
EA021565B1 (ru) 2015-07-30
US8796284B2 (en) 2014-08-05
BR112012024870B1 (pt) 2020-11-17
EA201201343A1 (ru) 2013-03-29
KR20130028732A (ko) 2013-03-19
MX2012011240A (es) 2012-11-30
ES2365960B1 (es) 2012-06-04
EP2552909A1 (en) 2013-02-06
JP2013523711A (ja) 2013-06-17
CA2795009C (en) 2016-06-21
CN102892761B (zh) 2015-02-04
BR112012024870A2 (pt) 2016-06-14

Similar Documents

Publication Publication Date Title
ME02100B (me) Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora
US20230116233A1 (en) Compounds And Compositions As Protein Kinase Inhibitors
Akhtar et al. Recent progress of benzimidazole hybrids for anticancer potential
CN101379060B (zh) 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
CN100355751C (zh) 2－取代的4－杂芳基－嘧啶、其组合物及其用途
AU2015279377B2 (en) Indolin-2-one or pyrrolo-pyridin-2-one derivatives
JP2011520915A5 (me)
HUE034979T2 (en) Aminopyrimidine derivatives for use as modulators of kinase activity
JP2004538260A (ja) 抗癌剤としてのサイクリン依存性キナーゼ阻害剤
CA2851082A1 (en) 1,3-substituted azetidine pde10 inhibitors
RU2415853C2 (ru) Бензимидазолы, применимые в качестве ингибиторов протеинкиназ
CN102573480B (zh) 三嗪衍生物及其治疗应用
WO2006071644A1 (en) Selective inhibitors of erk protein kinases and uses therof
Nemeth et al. Novel, selective CDK9 inhibitors for the treatment of HIV infection
Narasimhachar et al. Development of novel pyrimidine-thio-triazoles targeting EGFR in breast Cancer cells via one-pot copper-catalyzed 1, 3-dipolar cycloaddition
ME02551B (me) Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde- 10)
JP2016505059A5 (me)
RU2795572C2 (ru) Соединения и композиции для ингибирования ire1
AU2005203919A1 (en) Selective kinase inhibitors
HK1191936B (en) Compounds and compositions as protein kinase inhibitors
HK1188596A (en) Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease